Critical factors influencing prion inactivation by sodium hydroxide

Vox Sanguinis

Volumn 91, Issue 1, 2006, Pages 34-40

  Bauman, P A ^a   Lawrence, L A ^b   Biesert, L ^c   Dichtelmuller H ^d   Fabbrizzi, F ^e   Gajardo, R ^f   Groner A ^g   Jorquera, J I ^f   Kempf, C ^h   Kreil, T R ⁱ   Von Hoegen, I ^j   Pifat, D Y ^a   Petteway Jr , S R ^a   Cai, K ^a,k  

^a Talecris Biotherapeutics Inc   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c Octapharma   (Germany)

^d BIOTEST AG   (Germany)

^e Kedrion SpA   (Italy)

^f Grupo Grifols   (Spain)

^g ZLB Behring   (Germany)

^h ZLB Behring AG   (Switzerland)

ⁱ BAXTER BIOSCIENCE   (Austria)

^j Plasma Protein Therapeutics Association   (Belgium)

^k NONE   (United States)

more..

Author keywords

Inactivation; NaOH; Prion; Sarkosyl; TSE

Indexed keywords

ANTIBODY; ANTIBODY 3F4; CORE PROTEIN; DETERGENT; EPITOPE; PRION PROTEIN; PROTEINASE K; PROTEINASE RESISTANT CORE PRION PROTEIN; SODIUM HYDROXIDE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; BIOCHEMISTRY; BRAIN HOMOGENATE; CONFORMATIONAL TRANSITION; DEGENERATIVE DISEASE; DISINFECTION; HAMSTER; IMMUNOPRECIPITATION; IN VITRO STUDY; LIPID MEMBRANE; NONHUMAN; PLASMA; PRION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN CONTENT; PROTEIN DEGRADATION; PROTEIN STRUCTURE; SCRAPIE; VIRUS INACTIVATION; VIRUS INFECTIVITY; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL ASSAY; CRICETINAE; DECONTAMINATION; ENDOPEPTIDASE K; PRION DISEASES; PRPSC PROTEINS; SARCOSINE; SODIUM HYDROXIDE;

EID: 33744739156     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2006.00790.x     Document Type: Article

References (34)

1. Prusiner SB: Prions. Proc Natl Acad Sci USA 1998 95: 13363 13383
2. Prusiner SB: Novel proteinaceous infectious particles cause scrapie. Science 1982 216: 136 144
3. Morrissey MP Shakhnovich EI: Evidence for the role of PrPC helix 1 in the hydrophilic seeding of prion aggregates. Proc Natl Acad Sci USA 1999 96: 11293 11298
4. Bolton DC McKinley MP Prusiner SB: Molecular characteristics of the major scrapie prion protein. Biochemistry 1984 23: 5898 5906
5. McKinley MP Bolton DC Prusiner SB: A protease-resistant protein is a structural component of the scrapie prion. Cell 1983 35: 57 62
6. Belay ED Schonberger LB: The Public Health Impact of Prion diseases. Annu Rev Public Health 2005 26: 5.1 5. 5.22
7. Hill AF Desbruslais M Joiner S Sidle KCL Gowland I Collinge J: The same prion strain causes vCJD and BSE. Nature 1997 389: 448 450
8. Smith PG Bradley R. Bovine spongiform encephalopathy (BSE) and its epidemiology. Br Med Bull 2003 66: 185 198
9. Hunter N Foster J Chong A McCutcheon S Parnham D Eaton S MacKenzie C Houston F: Transmission of prion disease by blood transfusion. J Gen Virol 2002 83: 2897 2905
10. Llewelyn CA Hewitt PE Knight RS Amar K Cousens S Mackenzie J Will RG: Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004 363: 417 421
11. Peden AH Head MW Ritchie DL Bell JE Ironside JW: Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004 364: 527 529
12. Anon: New Case of Variant CJD Associated with Blood Transfusion. United Kingdom Health Protection Agency press statement of February 9, 2006. Accessed on May 2, 2006 at http://www.hpa.org.uk/hpa/news/articles/pressreleases/2006/ 060209ejd.htm
13. Hilton DA Ghani AC Conyers L Edwards P McCardle L Ritchie D Penney M Hegazy D Ironside JW: Prevalence of lymphoreticular prion protein accumulated in UK tissue samples. J Pathol 2004 203: 733 739
14. Prusiner S Groth DF McKinley MP Cochran SP Bowman KA Kasper KC: Thiocyanate and hydroxyl ions inactivate the scrapie agent. Proc Natl Acad Sci USA 1981 78: 4606 4610
15. Brown P Rohwer RG Gajdusek DC. Newer data on the inactivation of scrapie virus or Creutzfeldt-Jakob disease virus in brain tissue. J Infect Dis 1986 153: 1145 1148
16. Tateishi J Tashima T Kitamoto T: Practical methods for chemical inactivation of Creutzfeldt-Jakob disease pathogen. Microbiol Immunol 1991 35: 163 166
17. Taylor DM Fraser H McConnell I Brown DA Brown KL Lamza KA Smith GR: Decontamination studies with the agents of bovine spongiform encephalopathy and scrapie. Arch Virol 1994 139: 313 326
18. Whiteman MD Sofer G Montalto JG: A Case Study for the Inactivation of TSE Agents: Using Alkaline Treatment in the Manufacturing Process of a Cell Culture Media Supplement. BIOPHARM International September 2003. Accessed on May 2, 2006 at http://www.biopharminternational.com/biopharm/article/articleDetail.jsp? id=238838&&pageID=1
19. Käsermann F Kempf C: Sodium hydroxide renders the prion protein PrPSc sensitive to proteinase K. J Gen Virol 2003 84: 3173 3176
20. Baier M Schwarz A Mielke M: Activity of an alkaline 'cleaner' in the inactivation of the scrapie agent. J Hosp Infect 2004 57: 80 84
21. Fichet G Comoy E Duval C Antloga K Dehen C Charbonnier A McDonnell G Brown P Lasmézas CI Deslys JP: Novel methods for disinfection of prion-contaminated medical devices. Lancet 2004 364: 521 526
22. Lemmer K Mielke M Pauli G Beekes M: Decontamination of surgical instruments from prion proteins: in vitro studies on the detachment, destabilization and degradation of PrPSc bound to steel surfaces. J Gen Virol 2004 85: 3805 3816
23. Taylor DM: Inactivation of transmissible degenerative encephalopathy agents: a review. Vet J 2000 159: 10 17
24. Hartwell RC Nelson MS Kislan MM Stenland CJ Miller JLC Pifat DY Petteway SR Jr. Cai K: An improved Western blot assay to assess the clearance of prion protein from plasma-derived therapeutic proteins. J Virol Methods 2005 125: 187 193
25. Lee DC Stenland CJ Hartwell RC Ford EK Cai K Miller JLC Gilligan KJ Rubenstein R Fournel M Petteway SR Jr.: Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein. J Virol Methods 2000 84: 77 89
26. Stenland CJ Lee DC Brown P Petteway SR Jr. Rubenstein R: Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma. Transfusion 2002 42: 1497 1500
27. Lee DC Stenland CJ Miller JLC Cai K Ford EK Gilligan KJ Hartwell RC Terry JC Rubenstein R Fournel M Petteway SR Jr.: A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion 2001 41: 449 455
28. Silveira JR Raymond GJ Hughson AG Race RE Sim VL Hayes SF Caughey B: The most infectious prion protein particles. Nature 2005 437: 257 261
29. Kascsak R Rubenstein R Merz PA Tonna-DeMasi M Fersko R Carp RI Wisniewski HM Diringer H: Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol 1987 61: 3688 3693
30. Kascsak RJ Fersko R Pulgiano D Rubenstein R Carp RI: Immunodiagnosis of prion disease. Immunol Invest 1997 26: 259 268
31. Peretz D Williamson RA Matsunaga Y Serban H Pinilla C Bastidas RB Rozenshteyn R James TL Houghten RA Cohen FE Prusiner SB Burton DR: A conformational transition at the N-terminus of the prion protein features in formation of the scrapie isoform. J Mol Biol 1997 273: 614 622
32. Prusiner SB Hadlow WJ Garfin DE Cochran SP Baringer JR Race RE Eklund CM: Partial purification and evidence for multiple molecular forms of the scrapie agent. Biochemistry 1978 17: 4993 4999
33. McKinley MP Meyer RK Kenaga L Rahbar F Cotter R Serban A Prusiner SB: Scrapie prion rod formation in vitro requires both detergent extraction and limited proteolysis. J Virol 1991 65:1340 1351
34. Soto C: Diagnosing prion diseases: needs, challenges and hopes. Nat Rev Microbiol 2:809 819